Utility of molecular alterations in lymphoid diseases
| . | Gene . | Disease . | Drug . |
|---|---|---|---|
| Diagnosis | BRAF V600E | Hairy cell leukemia, Langerhans cell histiocytosis | |
| MAP2K1 | Variant hairy cell leukemia | ||
| MVD88 L265P | Waldenstrom macroglobulinemia | ||
| STAT3, STAT5B | T-cell large granular lymphocyte leukemia | ||
| RHOAG17V | Angioimmunoblastic T-cell lymphoma | ||
| TCF3, ID8 | Burkitt Lymphoma | ||
| Prognosis | IKZF1 deletion | B-cell ALL (poor) | |
| ERG deletion | B-cell ALL (good) | ||
| TP53 | Most (poor) | ||
| NOTCH 1 | CLL | ||
| SF3B1 | CLL | ||
| EZH2; ARID1A; EP300; FOX 01; MEF2B; CREBBP; CARDl1 | Follicular lymphoma (M7-FLIPI) | ||
| NOTCH 2 | Splenic marginal zone lymphoma | ||
| Therapeutic target | BRAF V600E | Hairy cell leukemia, Langerhans cell histiocytosis | BRAF inhibitors |
| BCR-ABL | B-cell ALL | Tyrosine kinase inhibitors | |
| ABL1 class Ph+-like fusions | B-cell ALL | Tyrosine kinase inhibitors | |
| JAK2; CRLF2 | B-cell ALL | Ruxolitinib (trials) | |
| ABL1 kinase mutations | Tyrosine kinase inhibitors | ||
| BTK C451S; PCLG2; CXCR4 | Ibrutinib | ||
| Other recurrent alterations with unclear clinical utility | ATM; BCL2; BCL6; PIMl; S0CS1; STAT6; PTEN; S1PR2; CD28; GNA13; CD79B; TNFAIP3; PRDM1; CDKN1B; CDKN2A/B;NT5C2; PAZ5; PHF6; PLCG1; JAK1; JAK3; NRAS; KRAS; PTPN11; PRKCB; DDX3X; SETD2; WHSC1 |
| . | Gene . | Disease . | Drug . |
|---|---|---|---|
| Diagnosis | BRAF V600E | Hairy cell leukemia, Langerhans cell histiocytosis | |
| MAP2K1 | Variant hairy cell leukemia | ||
| MVD88 L265P | Waldenstrom macroglobulinemia | ||
| STAT3, STAT5B | T-cell large granular lymphocyte leukemia | ||
| RHOAG17V | Angioimmunoblastic T-cell lymphoma | ||
| TCF3, ID8 | Burkitt Lymphoma | ||
| Prognosis | IKZF1 deletion | B-cell ALL (poor) | |
| ERG deletion | B-cell ALL (good) | ||
| TP53 | Most (poor) | ||
| NOTCH 1 | CLL | ||
| SF3B1 | CLL | ||
| EZH2; ARID1A; EP300; FOX 01; MEF2B; CREBBP; CARDl1 | Follicular lymphoma (M7-FLIPI) | ||
| NOTCH 2 | Splenic marginal zone lymphoma | ||
| Therapeutic target | BRAF V600E | Hairy cell leukemia, Langerhans cell histiocytosis | BRAF inhibitors |
| BCR-ABL | B-cell ALL | Tyrosine kinase inhibitors | |
| ABL1 class Ph+-like fusions | B-cell ALL | Tyrosine kinase inhibitors | |
| JAK2; CRLF2 | B-cell ALL | Ruxolitinib (trials) | |
| ABL1 kinase mutations | Tyrosine kinase inhibitors | ||
| BTK C451S; PCLG2; CXCR4 | Ibrutinib | ||
| Other recurrent alterations with unclear clinical utility | ATM; BCL2; BCL6; PIMl; S0CS1; STAT6; PTEN; S1PR2; CD28; GNA13; CD79B; TNFAIP3; PRDM1; CDKN1B; CDKN2A/B;NT5C2; PAZ5; PHF6; PLCG1; JAK1; JAK3; NRAS; KRAS; PTPN11; PRKCB; DDX3X; SETD2; WHSC1 |